A prespecified analysis of EMPEROR-Preserved indicates benefits of empagliflozin for people with heart failure and mildly reduced or preserved left ventricular ejection fraction.
People who have heart failure with preserved ejection fraction benefit from dapagliflozin irrespective of whether they have normal or impaired glucose metabolism, shows further analysis of DELIVER.
A flurry of publications accompanying the primary findings of DELIVER shows dapagliflozin to benefit a wide range of people who have heart failure with preserved ejection fraction.
SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.
Dapagliflozin significantly reduces the risk for worsening heart failure or cardiovascular death in people who have heart failure with preserved ejection fraction, show the results of the DELIVER trial.
The rate of heart failure hospitalization rises more than the rate of major adverse cardiovascular events as vascular risk increases in people with type 2 diabetes, report researchers.